Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective

Table 5

Estimated costs secondary to excess NSHEs due to SU utilization versus SGLT2i after metformin.

Scenarios (compounded estimate)	Outcome in CDN$ for 2016
Total indirect costs including work productivity and out of pocket	26.7M
Out-of-pocket costs	5.2M
Lost productivity	21.5M
NSHE and self-treated (only direct cost)	4.6M

Scenario assumptions: included only patients between 20 and 65; incorporated average income loss and costs; have not incorporated underreporting for NSHEs in real-world clinical settings; average compounded incidence probability for NSHEs is 3 events per patient per year.